National Bleeding Disorders Foundation

What National Bleeding Disorders Foundation does

The National Bleeding Disorders Foundation (NBDF), formerly the National Hemophilia Foundation, is a US 501(c)(3) nonprofit founded in 1948 and headquartered in New York. The organization serves individuals and families affected by inheritable blood and bleeding disorders, including hemophilia A, hemophilia B, von Willebrand disease, rare factor deficiencies, and inherited platelet disorders, with a particular programmatic focus in 2026 on addressing underdiagnosis in women and girls. NBDF operates a distributed service delivery model: a national office in New York coordinates 50+ state and regional chapters, partnerships with the CDC-recognized Hemophilia Treatment Center (HTC) network, and a cooperative education consortium with the Indiana Hemophilia & Thrombosis Center, Hemophilia Foundation of Michigan, Hemophilia Alliance, and the American Thrombosis & Hemostasis Network. Its product surface spans clinical fellowship programs (NBDF-Takeda Clinical Fellowship, Nursing, Physical Therapy, and Social Work Excellence Fellowships), research grants (Judith Graham Pool Postdoctoral Research Fellowship, NBDF-Sanofi Career Development Award), the peer-reviewed Bleeding Disorders Care & Practice journal, the PartnersPRN online education platform, the coreHem Mental Health Tool, the Community Voices in Research (CVR) platform hosted by IQVIA, and the Pathway to Cures venture philanthropy fund. The foundation's revenue model is multi-stream: individual donations (including planned giving, donor-advised funds, securities, and cryptocurrency), corporate sponsorships from major pharmaceutical partners (Sanofi, Kedrion BioPharma, Genentech, Pfizer, Takeda), and grants including a CDC Cooperative Agreement (NU01DD000006); all programmatic services are delivered free of charge to patients and families. NBDF's go-to-market is community-led, relying on the chapter network, HTCs, annual Bleeding Disorders Conference, Washington Days advocacy events, and multi-channel awareness campaigns (notably the 2026 'Educate to Elevate' campaign and Bleeding.org LIVE! livestream) to reach patients, healthcare providers, and policymakers.

Name

National Bleeding Disorders Foundation

Legal name

National Bleeding Disorders Foundation

Website

https://bleeding.org

Company type

Private

Founded year

1948

Operating status

Operating

Headcount range

101–250 employees

Short description

The National Bleeding Disorders Foundation (NBDF) is a US nonprofit founded in 1948 that serves individuals and families affected by inheritable bleeding disorders through a 50+ chapter network, clinical fellowships, research grants, MASAC clinical guidelines, and a peer-reviewed journal, funded by donations, pharmaceutical sponsorships, and a CDC cooperative agreement.

Ownership category

akta.pro rank

Product category

Nonprofit Patient Advocacy and Health Foundation

NAICS

Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)

SIC

Services-Health Services (8000)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

Keywords

• Bleeding disorders advocacy
• Nonprofit health foundation
• Hemophilia patient education
• Clinical fellowship programs
• Bleeding disorders research

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Others, Marketing or Sales, Technology or R&D

Revenue model

1. Donations and Fundraising: The foundation raises funds through individual donations, planned giving, donor advised funds, and monthly giving programs. They also receive donations of securities and cryptocurrency.
2. Corporate Partnerships: Corporate sponsors including Sanofi, Kedrion BioPharma, Genentech, Pfizer, and Takeda provide financial support for campaigns, educational programs, and clinical fellowships.
3. Grants: The foundation receives grant funding including CDC Cooperative Agreement (NU01DD000006) for education and public health initiatives.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels9 records

Core offering

NBDF is a 501(c)(3) nonprofit foundation that provides education, advocacy, research funding, and community support services for individuals and families affected by inheritable bleeding disorders such as hemophilia A, hemophilia B, von Willebrand disease, and rare factor deficiencies. It operates a nationwide network of 50+ state chapters and partners with the CDC-recognized Hemophilia Treatment Center system to deliver patient education, clinical fellowships (NBDF-Takeda, Nursing, PT, SW Excellence), postdoctoral research grants, peer-reviewed publications, MASAC clinical guidelines, and the Pathway to Cures venture philanthropy fund.

Product overview

The National Bleeding Disorders Foundation (NBDF) offers a comprehensive portfolio of education, research, and advocacy programs for individuals with bleeding disorders. The foundation provides clinical fellowship programs (NBDF-Takeda Clinical Fellowship, Nursing Excellence Fellowship, Physical Therapy Excellence Fellowship, Social Work Excellence Fellowship), research funding through the Judith Graham Pool Postdoctoral Research Fellowship and NBDF-Sanofi Career Development Award, and venture philanthropy via Pathway to Cures. Education offerings include the Partners in Bleeding Disorders Education program, Online Education for Providers platform, NBDF's Collaborative Learning Exchange, and the Wednesday Webinar Series. The foundation publishes the peer-reviewed Bleeding Disorders Care & Practice journal and maintains the Community Voices in Research (CVR) platform and coreHem Mental Health Tool. The Educate to Elevate multi-year awareness campaign features celebrity advocates, while MASAC Documents provide clinical guidelines. Annual events include the Bleeding Disorders Conference and Washington Days advocacy event.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Only 4% of 10,527 females with bleeding disorders had been screened for iron deficiency, while 72% met criteria for iron deficiency - addressed by new MASAC screening recommendations
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

15 partnerships are on record, tiered portfolio company, major, research collaborator and core.

• Spark Biomedicalportfolio companyStrategic or Co-development Partner · 24 March 2026Spark Biomedical is a portfolio company of Pathway to Cures (NBDF's venture philanthropy fund). They are conducting the LUNA Trial for transcutaneous auricular neurostimulation treatment for heavy menstrual bleeding.
• SanofimajorGTM or Marketing PartnerCorporate partner providing financial support for the Educate to Elevate campaign and other foundation initiatives. Sanofi supports awareness and education efforts for bleeding disorders.
• Kedrion BioPharmamajorGTM or Marketing PartnerCorporate partner supporting NBDF awareness campaigns and educational programming for the bleeding disorders community.
• GenentechmajorGTM or Marketing PartnerCorporate partner providing support for the Educate to Elevate campaign and other foundation initiatives.
• PfizermajorGTM or Marketing PartnerCorporate sponsor for Bleeding.org LIVE! event, supporting the first celebrity-driven national event for the bleeding disorders community.
• Oregon Health & Science Universityresearch collaboratorStrategic or Co-development PartnerCollaborating institution for the LUNA Trial, conducting Phase II clinical study on transcutaneous auricular neurostimulation.
• University of Michiganresearch collaboratorStrategic or Co-development PartnerCollaborating institution for the LUNA Trial, contributing to the decentralized clinical study evaluation.
• Yale Universityresearch collaboratorStrategic or Co-development PartnerCollaborating institution for the LUNA Trial, participating in the multi-site clinical study.
• Pathway to CurescoreOthersNBDF's venture philanthropy fund that invests in companies developing treatments for bleeding disorders. Parent organization relationship.
• CDC Cooperative AgreementcoreStrategic or Co-development PartnerCDC Coop Agreement (NU01DD000006) supporting NBDF's education and public health initiatives for bleeding disorders.
• Indiana Hemophilia & Thrombosis CentermajorStrategic or Co-development PartnerCooperative partner in the Partners in Bleeding Disorders Education program, providing multidisciplinary education for HTC network staff since 1996.
• Hemophilia Foundation of MichiganmajorStrategic or Co-development PartnerCooperative partner in the Partners in Bleeding Disorders Education program supporting HTC network education.
• Hemophilia AlliancemajorStrategic or Co-development PartnerCooperative partner in the Partners in Bleeding Disorders Education program.
• American Thrombosis & Hemostasis NetworkmajorStrategic or Co-development PartnerCooperative partner in the Partners in Bleeding Disorders Education program.
• Talk About ItmajorStrategic or Co-development PartnerEntertainment industry partner collaborating with NBDF to produce Bleeding.org LIVE!, the first celebrity-driven national event for the bleeding disorders community.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Cystic Fibrosis Foundation: The Cystic Fibrosis Foundation is a voluntary health organization with a similar structure to NBDF: disease-specific patient support, a research grantmaking arm, a venture philanthropy model (e.g., founding stake in Vertex therapies), clinical guidelines, and an HTC-like care center network. Highly comparable in mission, revenue model, and programmatic mix.
• Leukemia & Lymphoma Society: LLS is a large voluntary health nonprofit with comparable programmatic pillars (research funding, patient education, advocacy, healthcare professional engagement) and a track record of sustained pharma sponsorship. Comparable in scale and diversification of funding streams beyond hemophilia/bleeding disorders.
• American Cancer Society: ACS operates the same broad disease-specific nonprofit blueprint — research grants, patient services, advocacy, survivor support — at much larger scale. Useful as a broad incumbent comparable even though its mission area (cancer) is broader than bleeding disorders.

Direct peers

• Muscular Dystrophy Association: MDA is a voluntary health nonprofit that similarly funds research fellowships, runs a clinic/care-center network (MDA Care Centers), publishes clinical guidance, advocates federally, and accepts pharma corporate sponsorships. Directly comparable in patient-services-plus-research-plus-advocacy model.
• National Multiple Sclerosis Society: The National MS Society operates a comparable model with disease-specific patient support, research grants, a professional fellowship pipeline, federal advocacy, and a regional chapter structure. Analogous in scope, donor model, and chronic-disease focus.
• ALS Association: The ALS Association is a voluntary health nonprofit combining research funding, clinical care network (ALS Certified Centers), advocacy, and pharma/corporate partnerships. Comparable in rare/chronic disease programming, federal advocacy focus, and disease-modifying treatment pipelines.
• JDRF (formerly Juvenile Diabetes Research Foundation): JDRF is a disease-specific voluntary health organization funding research, providing patient support, running advocacy campaigns, and operating a chapter network — directly comparable to NBDF's structure, and notably a pioneer in venture philanthropy for type 1 diabetes that Pathway to Cures emulates.
• Sickle Cell Disease Association of America: SCDAA is a comparable disease-specific voluntary health nonprofit addressing a hematologic condition with strong racial/gender health-equity dimensions, federal advocacy, and pharma partnerships. Structurally and operationally a near-twin to NBDF in scope, though addressing a different hematologic disease.

Emerging players

• National Organization for Rare Disorders (NORD): NORD is an umbrella rare-disease nonprofit providing patient support, federal advocacy (including the Orphan Drug Act), and research grants across many diseases. Comparable as a cross-disease advocacy and policy peer, though NBDF operates disease-specifically rather than cross-cutting.

Others

• American Thrombosis & Hemostasis Network (ATHN): ATHN is a non-profit coordinating data infrastructure across Hemophilia Treatment Centers and partners with NBDF in the Partners in Bleeding Disorders Education program. Comparable as a mission-adjacent organization operating in the same clinical and research ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/NHF_Hemophilia
• YouTubeyoutube.com/@NBDFvideo
• LinkedInlinkedin.com/company/national-bleeding-disorders-foundation
• Facebookfacebook.com/NationalHemophiliaFoundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Bleeding Disorders Foundation